Adi Kozminsky-Atias
Adi Kozminsky-Atias has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Elaine Se Stokes
BioPhorum Operations Group, BioPhorum, The Gridiron Building, 1 Pancras Square, London, N1C 4AG, UK
1 shared publication - Esther Hq Ong
Nonclinical Pharmacology, Fresenius Kabi SwissBioSim GmbH, Terre Bonne Business Park, Route de Crassier 23-A3, Eysins, CH1262, Switzerland
1 shared publication - Eva Martinez
UCB Pharma, Chemin du Foriest, Braine-l’Alleud, 1420, Belgium
1 shared publication - Isam Qahwash
Biologics Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, NJ08903, USA
1 shared publication - Jan Amstrup
Chemistry, Manufacturing & Controls Bioanalysis, Novo Nordisk, Novo Nordisk Park, Maloev, 2760, Denmark
1 shared publication - Jenny Wang
Gilead Sciences, Inc., 4010 Ocean Ranch Blvd, Oceanside, CA 92056, USA
1 shared publication
Latest Publications
- Open Access
- 9 February 2024
- Published by Taylor & Francis in BioTechniques
- Vol. 76 (4) , 135-144
An Industry Perspective Approach and Control Strategy for Implementation of Ready-to-Use Cells in Bioassays: Survey Outcome And Recommendations
The BioPhorum Development Group is an industry collaboration enabling the sharing of common practices for the development of biopharmaceuticals. Bioassays are an important part of an analytical con... Method summary Draft questions were composed by the authors based on prior knowledge of the issues associated with ready-to-use cell use. Questions were further refined through open discussion amon...
- 9 February 2024
- Published by Taylor & Francis in BioTechniques
- Vol. 76 (4) , 135-144
Open AccessAn Industry Perspective Approach and Control Strategy for Implementation of Ready-to-Use Cells in Bioassays: Survey Outcome And Recommendations
The BioPhorum Development Group is an industry collaboration enabling the sharing of common practices for the development of biopharmaceuticals. Bioassays are an important part of an analytical con... Method summary Draft questions were composed by the authors based on prior knowledge of the issues associated with ready-to-use cell use. Questions were further refined through open discussion amon...
- Open Access
- 18 October 2011
- Published by Wiley in The FASEB Journal
- Vol. 26 (2) , 576-586
Molding the business end of neurotoxins by diversifying evolution
A diverse range of organisms utilize neurotoxins that target specific ion channels and modulate their activity. Typically, toxins are clustered into several multigene families, providing an organism with the upper hand in the never‐ending predator‐prey arms race. Several gene families, including those encoding certain neurotoxins, have been subject to diversifying selection forces, resulting in rapid gene evolution. Here we sought a spatial pattern in the distribution of both diversifying and purifying selection forces common to neurotoxin gene families. Utilizing the mechanistic empirical combination model, we analyzed various toxin families from different phyla affecting various receptors and relying on diverse modes of action. Through this approach, we were able to detect clear correlations between the pharmacological surface of a toxin and rapidly evolving domains, rich in positively selected residues. On the other hand, patches of negatively selected residues were restricted to the nontoxic face of the molecule and most likely help in stabilizing the tertiary structure of the toxin. We thus propose a mutual evolutionary strategy of venomous animals in which adaptive molecular evolution is directed toward the toxin active surface. Furthermore, we propose that the binding domains of unstudied toxins could be readily predicted using evolutionary considerations.—Kozminsky‐Atias, A., Zilberberg, N. Molding the business end of neurotoxins by diversifying evolution. FASEB J. 26, 576–586 (2012). www.fasebj.org
- 18 October 2011
- Published by Wiley in The FASEB Journal
- Vol. 26 (2) , 576-586
Open AccessMolding the business end of neurotoxins by diversifying evolution
A diverse range of organisms utilize neurotoxins that target specific ion channels and modulate their activity. Typically, toxins are clustered into several multigene families, providing an organism with the upper hand in the never‐ending predator‐prey arms race. Several gene families, including those encoding certain neurotoxins, have been subject to diversifying selection forces, resulting in rapid gene evolution. Here we sought a spatial pattern in the distribution of both diversifying and purifying selection forces common to neurotoxin gene families. Utilizing the mechanistic empirical combination model, we analyzed various toxin families from different phyla affecting various receptors and relying on diverse modes of action. Through this approach, we were able to detect clear correlations between the pharmacological surface of a toxin and rapidly evolving domains, rich in positively selected residues. On the other hand, patches of negatively selected residues were restricted to the nontoxic face of the molecule and most likely help in stabilizing the tertiary structure of the toxin. We thus propose a mutual evolutionary strategy of venomous animals in which adaptive molecular evolution is directed toward the toxin active surface. Furthermore, we propose that the binding domains of unstudied toxins could be readily predicted using evolutionary considerations.—Kozminsky‐Atias, A., Zilberberg, N. Molding the business end of neurotoxins by diversifying evolution. FASEB J. 26, 576–586 (2012). www.fasebj.org